SeaStar Medical Provides Regulatory Update Related to its HDE Application for Pediatric Selective Cytopheretic Device
09 mai 2023 16h05 HE
|
SeaStar Medical Holding Corporation
DENVER, May 09, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation...
SeaStar Medical Reports 2022 Financial Results and Provides a Business Update
30 mars 2023 19h23 HE
|
SeaStar Medical Holding Corporation
DENVER, March 30, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce...
SeaStar Medical Holding Corporation Closes Initial $3.3 Million Tranche of $9.8 Million Private Placement
16 mars 2023 08h00 HE
|
SeaStar Medical Holding Corporation
DENVER, March 16, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce...
SeaStar Medical to Present at the Emerging Growth Virtual Conference on March 22, 2023
15 mars 2023 16h05 HE
|
SeaStar Medical Holding Corporation
DENVER, March 15, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce...
SeaStar Medical’s Selective Cytopheretic Device to be Featured at the 5th Chronic Kidney Disease Drug Development Summit
24 févr. 2023 08h05 HE
|
SeaStar Medical Holding Corporation
DENVER, Feb. 24, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce...
SeaStar Medical Announces Details of the Selective Cytopheretic Device Pivotal Study in Critically ill Adults with Acute Kidney Injury
15 févr. 2023 16h01 HE
|
SeaStar Medical Holding Corporation
The NEUTRALIZE-AKI study will evaluate safety and efficacy of the SCD’s ability to target and neutralize the highly activated proinflammatory neutrophils and monocytes that drive hyperinflammation ...
IR-MED SIGNS AGREEMENT TO EXPAND ITS PRESSURESAFE DEVICE USABILITY STUDY
14 févr. 2023 09h15 HE
|
IR-Med, Inc.
The study will expand to Rabin Medical Center (RMC), in parallel to Beit-Rivka, turning the study to a double center usability study. Rosh Pinna, Israel, Feb. 14, 2023 (GLOBE NEWSWIRE) --...
IR-Med Signs Agreement for the Commercial Design of the PressureSafe Device
30 août 2022 09h15 HE
|
IR-Med, Inc.
Rosh Pinna, Israel, Aug. 30, 2022 (GLOBE NEWSWIRE) -- (“IR-MED or the “Company”) (OTCQB:IRME), an innovative medical device company that is developing non-invasive, real-time detection devices...
IR-Med To Initiate Useability Study of its PressureSafe Device
23 juin 2022 09h15 HE
|
IR-Med, Inc.
Rosh Pinna, Israel, June 23, 2022 (GLOBE NEWSWIRE) -- (“IR-MED or the “Company”) (OTCQB:IRME), an innovative development stage medical device company that utilizes Infra-Red light spectroscopy (IR)...
Neovasc Comments on European Heart Journal Publication
28 avr. 2022 09h05 HE
|
Neovasc, Inc.
Report demonstrates objective improvements in patients suffering from microvascular dysfunction VANCOUVER and MINNEAPOLIS, April 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc....